The Role Of Infant Food Allergy In The Natural History And Burden Of Allergic Disease Across The Early Years: The HealthNuts Study
Funder
National Health and Medical Research Council
Funding Amount
$1,722,373.00
Summary
The HealthNuts study of 4600 infants is the world’s first comprehensive population-based study of food allergy with objective measurement of true food allergy and will enable us to understand better the natural history of allergic disorders including food allergy, asthma, eczema and allergic rhinitis and the interplay of risk factors for development of these conditions in the first 6 years of life. The study will have important implications for clinical guidelines and public health policy.
Population Prevalence And Environmental-genetic Predictors Of Food Allergy In An Infant Cohort
Funder
National Health and Medical Research Council
Funding Amount
$551,642.00
Summary
This study will measure which children are at greatest risk of food allergy. We plan to recruit 5000 children to test for food allergies, as well as asking a range of questions on different lifestyle factors such as diet and history of allergies . If positive, participants will be invited to a hospital clinic for tests and treatment. This will allow us to describe the epidemiology of food allergy, and assist the development of better services for those with food allergy in the community.
Harnessing Information Technology To Improve Self-management Behaviours And Health Outcome In People With Heart Failure: A Smarthome Ecosystem Living Lab Study
Funder
National Health and Medical Research Council
Funding Amount
$1,120,226.00
Summary
The burden of heart failure in Australia is substantial. Management of heart failure is complex and requires self-management of symptoms and behaviour change, which requires ongoing education and support to achieve. Current approaches for supporting self-management do not meet the needs of people with heart failure or the healthcare system. This Australian first project aims to co-design an intelligent smart home ecosystem (Smart Heart) to support the management for people with heart failure.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
Which Heart Failure Intervention Is Most Cost-effective And Consumer Friendly In Reducing Hospital Care: The Which
Funder
National Health and Medical Research Council
Funding Amount
$921,640.00
Summary
Chronic heart failure (CHF) is a costly, debilitating and deadly condition that has reached near epidemic proportions in Australia. In the absence of a permanent cure for CHF, the number of people affected by CHF has risen beyond 350,000 and is expected to increase by 20-30% in the next 20 years. We recently reviewed the benefits of applying nurse-led, CHF management programs (CHF-MPs) to typically old and fragile patients, in whom recurrent hospital admissions and a premature death are common. ....Chronic heart failure (CHF) is a costly, debilitating and deadly condition that has reached near epidemic proportions in Australia. In the absence of a permanent cure for CHF, the number of people affected by CHF has risen beyond 350,000 and is expected to increase by 20-30% in the next 20 years. We recently reviewed the benefits of applying nurse-led, CHF management programs (CHF-MPs) to typically old and fragile patients, in whom recurrent hospital admissions and a premature death are common. We confirmed the results of pioneering Australian research that CHF-MPs dramatically improve health outcomes in CHF. CHF-MPs now form part of the recommended gold-standard management of CHF. However, we also have evidence that only a small proportion of patients are exposed to a CHF-MP in Australia. Residual issues such as consumer preference and the cost of applying these programs are hindering their wide-spread application. The WHICH? Study addresses this _road block� to implementing a potentially valuable health care service by tackling a number of critical issues: which form of CHF-MP (home or specialist clinic-based follow-up), will produce the best health outcomes, save the most money and meet the needs of consumers at the same time? To answer this question, we will undertake a randomised, head-to-head study of a home versus clinic-based CHF-MP, in 1000 recently hospitalised CHF patients recruited from SA, VIC, NSW and QLD. Patterns and of health care and consumer preferences and quality of life will then be compared for these two different forms of CHF-MP from a combined health economic, health policy and consumer perspective to determine the best form of CHF-MP to be applied. A _consensus� vision for applying an Australia-wide service will then be developed. The potential impact of the results of the study will then be modelled on the status of Australian CHF-MPs in the year 2010 and a blue-print for action devised.Read moreRead less
Prevention Of Complications In Type 2 Diabetes By Using ICT To Optimise Self-management
Funder
National Health and Medical Research Council
Funding Amount
$849,181.00
Summary
The impact of the diabetes epidemic on individuals and society is severe but can be reduced by improving diabetes self-management. Conducted in partnership with Diabetes Australia (Queensland, Victoria, WA) and Roche Diagnostics, this research will evaluate the 'real world' implementation of a telehealth program, already successfully trialled, which has the potential to provide a low cost and effective program to a large number of Australians with type 2 diabetes.